Table 2. Clinicopathological characteristics of Group 1 (node negative ALND) versus Group 2 (node positive ALND).
| Parameters | Group 1 (node negative ALND) (n = 66) |
Group 2 (node positive ALND) (n = 62) |
Χ2 | p (univariate) | p (multivariate) |
|---|---|---|---|---|---|
| Age, years | |||||
| ≤50, no. (%) | 32 (48.5) | 30 (48.4) | 0.00 | 1.00, ns | 0.77, ns |
| >50, no. (%) | 34 (51.5) | 32 (51.6) | |||
| Clinical T stage,no. (%) | |||||
| T1 | 17 (25.8) | 5 (8.1) | 7.03 | 0.01 | 0.02 |
| T2 | 49 (74.2) | 57 (91.9) | |||
| Estrogen receptor, no. (%) | |||||
| ER+ | 54 (81.8) | 54 (87.1) | 0.67 | 0.47, ns | 0.16, ns |
| ER− | 12 (18.2) | 8 (12.9) | |||
| Progesterone receptor, no. (%) | |||||
| PR+ | 51 (77.3) | 54 (87.1) | 2.09 | 0.17, ns | 0.17, ns |
| PR− | 15 (22.7) | 8 (12.9) | |||
| Modified Bloom-Richardson score, no (%) | |||||
| Grade 1 | 2 (3) | 7 (11.3) | 0.18 (Fisher exact test), ns |
0.15, ns | |
| Grade 2 | 30 (45.5) | 24 (38.7) | |||
| Grade 3 | 34 (51.5) | 31 (50) | |||
| Tumor type, no. (%) | |||||
| Infiltrating ductal | 63 (95.5) | 57 (91.9) | 0.39 (Fisher exact test), ns |
0.26, ns | |
| Infiltrating lobular | 1 (1.5) | 4 (6.5) | |||
| Others | 2 (3) | 1 (1.6) | |||
| Size of SLN mets, no. (%) | |||||
| Micrometastasis | 20 (30.3) | 2 (3.2) | 16.46 | <0.001 | 0.001 |
| Macrometastasis | 46 (69.7) | 60 (96.8) |
ER = Estrogen receptor, PR = Progesterone receptor, ALND = Axillary lymph node dissection, SLN = Sentinel lymph node